Chimeric Antibody Market Report 2026

The chimeric antibody market size has grown rapidly in recent years. It will grow from $13.74 billion in 2025 to $15.36 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to early success of monoclonal antibody therapies, reliance on murine antibody technologies, increasing cancer prevalence, growth in autoimmune disease incidence, expanding research in immunology.

The chimeric antibody market size is expected to see rapid growth in the next few years. It will grow to $23.73 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to advancement in antibody engineering techniques, rising approvals of biologic drugs, expansion of personalized medicine, increasing investment in biopharmaceutical r&d, growing clinical pipeline of chimeric antibodies. Major trends in the forecast period include rising adoption of chimeric antibodies in oncology therapies, increasing use in autoimmune and inflammatory disease treatment, growing demand for target-specific monoclonal antibody therapies, expansion of recombinant dna and phage display technologies, improved safety and reduced immunogenicity compared to murine antibodies.

The increasing prevalence of cancer is expected to drive the growth of the chimeric antibody market in the coming years. Cancer prevalence refers to the total number of individuals, both newly diagnosed and previously diagnosed, living with a history of cancer at a specific point in time. The prevalence of cancer is rising due to lifestyle-related risk factors, including poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, which increase the likelihood of developing various cancers. Chimeric antibodies support cancer treatment by providing targeted therapies that specifically attack tumor cells, reducing side effects and improving patient outcomes and treatment efficacy. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023 - an average of 972 per day - representing 8,605 more cases than in 2022. Therefore, the increasing prevalence of cancer is fueling the growth of the chimeric antibody market.

Major companies in the chimeric antibody market are focusing on advanced therapies such as monoclonal antibodies to enhance treatment outcomes, improve survival rates, and address critical medical conditions. Monoclonal antibodies are laboratory-engineered proteins designed to mimic the immune system’s ability to target harmful pathogens, including viruses and inflammatory agents. For example, in June 2023, InflaRx N.V., a Germany-based biopharmaceutical company, commercially launched Gohibic (vilobelimab). This chimeric monoclonal antibody targets C5a in the complement system, blocking C5a-mediated immune responses to reduce excessive inflammation. It is used for treating COVID-19 in hospitalized adults when administered within 48 hours of starting invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). This therapy represents a significant advancement in controlling hyperinflammation in severe infections, providing a new treatment option for high-risk patients.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately $43 billion. Through this acquisition, Pfizer aims to strengthen its oncology portfolio by integrating Seagen’s antibody-drug conjugate (ADC) technology, approved cancer therapies, and promising late-stage pipeline candidates. Seagen Inc. is a US-based biopharmaceutical company developing chimeric antibody-based cancer treatments.

Major companies operating in the chimeric antibody market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Merck KGaA, BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc.

North America was the largest region in the chimeric antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chimeric antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chimeric antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the chimeric antibody market by increasing the cost of imported biologic raw materials, cell culture media, and advanced manufacturing equipment, affecting production timelines and overall therapy costs. Segments such as recombinant DNA-based antibodies and oncology applications are most affected, particularly in North America and Asia-Pacific regions that rely on cross-border supply chains. Despite these challenges, tariffs have encouraged local biologics manufacturing, technology transfer, and investment in domestic biopharmaceutical infrastructure, supporting long-term market stability.

The chimeric antibody market research report is one of a series of new reports that provides chimeric antibody market statistics, including chimeric antibody industry global market size, regional shares, competitors with a chimeric antibody market share, detailed chimeric antibody market segments, market trends and opportunities, and any further data you may need to thrive in the chimeric antibody industry. This chimeric antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chimeric antibodies are laboratory-engineered monoclonal antibodies that combine the variable (antigen-binding) region from a non-human species, typically a mouse, with the constant region of a human antibody. This design enhances compatibility with the human immune system while preserving high specificity for the target antigen.

The main types of chimeric antibodies include immunoglobulin G (IgG) chimeric antibodies, fragment antigen-binding (Fab) chimeric antibodies, and single-chain variable fragment (ScFv) chimeric antibodies. Immunoglobulin G (IgG) chimeric antibodies are constructed by fusing the variable region from a non-human species with the constant region of human IgG, reducing immunogenicity while maintaining antigen specificity. They are manufactured using processes such as recombinant DNA technology, hybridoma technology, phage display, and transgenic technology, and are administered via intravenous (IV), subcutaneous, and intramuscular routes. These antibodies are applied in various areas, including cancer therapy, autoimmune diseases, infectious diseases, and transplant rejection, and are utilized by pharmaceutical companies, research institutes, clinics and hospitals, and diagnostic laboratories.

The chimeric antibody market consists of sales of biosimilars of chimeric antibodies, diagnostic chimeric antibodies, and therapeutic chimeric antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.